Robert-Alain Toillon

Prof. Robert-Alain Toillon

University of Lille, Lille, Hauts-de-France, France
orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2006 in Endocrine-Related Cancer
Verified
Journal Article
Open access
PDF file
MLMarc Lacroix
Marc Lacroix
Robert-Alain ToillonRobert-Alain Toillon
Robert-Alain Toillon
Guy LeclercqGuy Leclercq
Guy Leclercq
P53 plays a key role in mediating cell response to various stresses, mainly by inducing or repressing a number of genes involved in cell cycle arrest, senescence, apoptosis, DNA repair, and angiogenesis. According to this important function, p53 activity is controlled in a very complex manner, including several auto-regulatory loops, through the intervention of dozens of modulator proteins (the ‘p53 interactome’). p53 mutations are observed in a significant minority of breast tumours. In the remaining cases, alterations of interactome components or target genes could contribute, to some extent, to reduce the ability of p53 to efficiently manage stress events. While the prognostic and predictive value of p53 is still debated, there is an increasing interest for p53-based therapies. The present paper aims to provide updated information on p53 regulation and function, with specific interest on its role in breast cancer.

1 May 2001 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SDSimon Descamps
Simon Descamps
Robert-Alain ToillonRobert-Alain Toillon
Robert-Alain Toillon
EAEric Adriaenssens
Eric Adriaenssens
VPValérie Pawlowski
Valérie Pawlowski
SCSimon M. Cool
Simon M. Cool
Hubert HondermarckHubert Hondermarck
Hubert Hondermarck
We show here that the neurotrophin nerve growth factor (NGF), which has been shown to be a mitogen for breast cancer cells, also stimulates cell survival through a distinct signaling pathway. Breast cancer cell lines (MCF-7, T47-D, BT-20, and MDA-MB-231) were found to express both types of NGF receptors: p140trkA and p75NTR. The two other tyrosine kinase receptors for neurotrophins, TrkB and TrkC, were not expressed. The mitogenic effect of NGF on breast cancer cells required the tyrosine kinase activity of p140trkA as well as the mitogen-activated protein kinase (MAPK) cascade, but was independent of p75NTR. In contrast, the anti-apoptotic effect of NGF (studied using the ceramide analogue C2) required p75NTR as well as the activation of the transcription factor NF-kB, but neither p140trkA nor MAPK was necessary. Other neurotrophins (BDNF, NT-3, NT-4/5) also induced cell survival, although not proliferation, emphasizing the importance of p75NTR in NGF-mediated survival. Both the pharmacological NF-κB inhibitor SN50, and cell transfection with IkBm, resulted in a diminution of NGF anti-apoptotic effect. These data show that two distinct signaling pathways are required for NGF activity and confirm the roles played by p75NTR and NF-κB in the activation of the survival pathway in breast cancer cells.

30 March 2009 in Oncogene
Verified
Journal Article
Closed access
CLC Lagadec
C Lagadec
SMS Meignan
S Meignan
EAE Adriaenssens
E Adriaenssens
BFB Foveau
B Foveau
EVE Vanhecke
E Vanhecke
XBX Le Bourhis
X Le Bourhis

1 November 2014 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
CMCoralie Moncharmont
Coralie Moncharmont
ALAntonin Levy
Antonin Levy
JGJean-Baptiste Guy
Jean-Baptiste Guy
AFAlexander T. Falk
Alexander T. Falk
MGMatthieu Guilbert
Matthieu Guilbert
NMNicolas Magné
Nicolas Magné

1 January 2006 in Cancer Letters
Verified
Journal Article
Closed access
NMNicolas Magné
Nicolas Magné
Robert-Alain ToillonRobert-Alain Toillon
Robert-Alain Toillon
VBVirginie Bottero
Virginie Bottero
Céline MirjoletCéline Mirjolet
Céline Mirjolet
PHPaul Van Houtte
Paul Van Houtte
JPJean-François Peyron
Jean-François Peyron

1 September 2004 in Endocrine-Related Cancer
Verified
Journal Article
Open access
PDF file
MLM Lacroix
M Lacroix
Robert-Alain ToillonRobert-Alain Toillon
Robert-Alain Toillon
Guy LeclercqGuy Leclercq
Guy Leclercq
It is widely believed that ductal breast cancer dissemination involves a succession of clinical and pathological stages starting with carcinoma in situ, progressing into invasive lesion and culminating in metastatic disease. Such changes have frequently been attributed to the sequential acquisition of various alterations in a single cell followed by clonal selection and expansion, thus leading to intra-tumor diversity. According to this multi-step view, extensive genotype and phenotype (marker expression, grade) shift may occur in the same tumor during progression; this may lead to the coexistence of molecularly and/or pathologically different areas within the same lesion. An increasing amount of data of various natures now appear to challenge this concept: only a few distinct ‘portraits’, in relation to estrogen receptor (ER) status and grade, may be found among tumors. Moreover, although undergoing increasing genetic alteration, most individual lesions largely maintain their phenotype when they evolve from in situ to the metastatic state. While many of the data presented here are related to ductal tumors, lobular cancer is also discussed.